Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Collaboration of the NIH and PHS Commissioned Corps in the International Ebola Clinical Research Response.

Pierson JF, Kirchoff MC, Orsega SM, Giberson SF, Herpin BR, Ready TW, Holshue ML, Kelly GG.

Fed Pract. 2017 Aug;34(8):18-25.

2.

Interferon-alpha produces significant decreases in HIV load.

Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC.

J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090.

3.

Development and implementation of clinical trial protocol templates at the National Institute of Allergy and Infectious Diseases.

Bridge H, Smolskis M, Bianchine P, Dixon DO, Kelly G, Herpin B, Tavel J; Protocol Template Working Group of the NIAID Clinical Research Subcommittee.

Clin Trials. 2009 Aug;6(4):386-91. doi: 10.1177/1740774509341482. Epub 2009 Jul 22.

4.

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.

Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC.

Hum Gene Ther. 2005 Sep;16(9):1065-74.

PMID:
16149905
5.

Increases in CD4+ T lymphocytes occur without increases in thymic size in HIV-infected subjects receiving interleukin-2 therapy.

Lu AC, Jones EC, Chow C, Miller KD, Herpin B, Rock-Kress D, Metcalf JA, Lane HC, Kovacs JA.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):299-303.

PMID:
14600575
6.

Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.

Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, Herpin B, Perry C, Hallahan CW, Davey RT, Metcalf JA, Connors M, Fauci AS.

J Infect Dis. 2002 Jan 1;185(1):61-8. Epub 2001 Dec 14.

PMID:
11756982
7.

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC.

J Exp Med. 2001 Dec 17;194(12):1731-41.

8.

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients.

Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane HC.

AIDS. 2001 Sep 28;15(14):1765-75.

PMID:
11579237
9.

Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion.

Miller KD, Spooner K, Herpin BR, Rock-Kress D, Metcalf JA, Davey RT Jr, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Lane HC.

Clin Immunol. 2001 Apr;99(1):30-42.

PMID:
11286539
10.
11.

Hepatitis G virus and human immunodeficiency virus coinfection: response to interferon-alpha therapy.

Lau DT, Miller KD, Detmer J, Kolberg J, Herpin B, Metcalf JA, Davey RT, Hoofnagle JH.

J Infect Dis. 1999 Oct;180(4):1334-7.

PMID:
10479167
12.

Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults.

Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT Jr, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC.

Nat Med. 1998 Jul;4(7):852-6.

PMID:
9662381
13.

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Davey RT Jr, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL, Lane HC.

Antimicrob Agents Chemother. 1996 Jul;40(7):1657-64.

14.

Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus.

Davey RT Jr, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, Cox SR, Polis MA, Kovacs JA, Falloon J, et al.

J Infect Dis. 1994 Nov;170(5):1180-8.

PMID:
7963711
15.

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.

Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, Deyton L, Davey RT Jr, Falloon J, et al.

Ann Intern Med. 1990 Jun 1;112(11):805-11.

PMID:
1971503
16.

Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma.

Deyton LR, Walker RE, Kovacs JA, Herpin B, Parker M, Masur H, Fauci AS, Lane HC.

N Engl J Med. 1989 Nov 2;321(18):1246-9. No abstract available.

PMID:
2638573
17.

Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma.

Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N, et al.

Lancet. 1988 Nov 26;2(8622):1218-22.

PMID:
2903954
18.

The nurse training act: yesterday, today, and...

Rubenfeld MG, Donley R, Falinski EG, Herpin BR, Horn P, Walker S.

Am J Nurs. 1981 Jun;81(6):1202-4. No abstract available.

PMID:
6909017

Supplemental Content

Loading ...
Support Center